* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download DMD Reviews 101 - Action Duchenne
Human genome wikipedia , lookup
Copy-number variation wikipedia , lookup
Genomic library wikipedia , lookup
Gene expression profiling wikipedia , lookup
Saethre–Chotzen syndrome wikipedia , lookup
Pathogenomics wikipedia , lookup
Gene desert wikipedia , lookup
Gene nomenclature wikipedia , lookup
Epigenetics of diabetes Type 2 wikipedia , lookup
Oncogenomics wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Point mutation wikipedia , lookup
Medical genetics wikipedia , lookup
Helitron (biology) wikipedia , lookup
Genome (book) wikipedia , lookup
History of genetic engineering wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
Genetic engineering wikipedia , lookup
Gene expression programming wikipedia , lookup
Public health genomics wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
No-SCAR (Scarless Cas9 Assisted Recombineering) Genome Editing wikipedia , lookup
Microevolution wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Genome evolution wikipedia , lookup
Gene therapy wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Research Review No. 101. New techniques to look out for. The Studies: The authors of the studies to be discussed in this review are working at the cutting edge of molecular biology and are linking these studies to finding a cure for Duchenne Muscular Dystrophy (DMD). The authors of the first paper to be reviewed from U.S.A. use the recently developed technique of CRISPRmediated Genome Editing in an attempt to restore Dystrophin expression and function in mdx mice (1). CRISPR stands for clustered regularly-interspaced short palindromic repeats. This technique has enormous potential applications, which including altering the germline of humans, animals and other organisms, and modifying the genes of food crops. In their studies, which are clearly presented and illustrated, they demonstrate that CRIPSR-mediated genome editing actually efficiently excised a 23-kb genomic region on the X-chromosome which included the mutated exon 23 in the mdx mouse model of DMD, and restored dystrophin expression as well as the dystrophin-glycoprotein complex at the sarcolemma of the skeletal muscles in live mdx mice. The prospect of this technique being applied to patients with DMD provides the exciting prospect of a ‘cure’ for DMD being developed. The authors conclude their summary of these studies by stating: “This study provides proof evidence for permanent gene correction in DMD.” The second paper to be discussed (2) is a brief review that considers that the use of both the CRISPR technique combined with the development of the viral vector techniques designed to transport the gene editing to the site, where it is needed. They close their review with the hopeful comments: “The simultaneous exploration of these different therapeutic strategies in parallel is therefore warranted and offers the best hope for those patients and their families, who are blighted by these devastating muscle disorders.” Another brief review (3) stresses the importance of the correct diagnosis of DMD, noting not just the large mutations in the dystrophin gene but also any small ones. The authors remind us that the dystrophin gene is the largest known human gene and that 1/3 of mutations are new. These facts underlie the situation that there are an enormous variety of mutations being described. The authors conclude their review with these words: ” Raising awareness with family physicians and other healthcare professionals who see young children could improve this further. Finally, given that new genetic therapies are emerging, one could consider offering neonatal screening for DMD.” Finally in the last study to be reviewed (4) also from U.S.A., we return to the topic of gene-editing. They describe the various methods of gene-editing that are being developed not just for DMD but for many other conditions as well, including viral and bacterial infections, blood disorders, liver problems, skin, eye and respiratory disorders, as well as DMD. They conclude that: “The rapid progress in the field is likely to continue to lead to new technologies that will expand the scope of genome-editing. Alternative genome-editing technologies, such as targetable site-specific recombinases that do not rely on the creation of double-strand breaks, alternative CRISPR systems with unique properties, and DNA-guided nuclease systems will continue to change what is possible with these tools.” However, they introduce a note of caution in their final words, with which I fully concur: “In summary, genome editing has changed the definition of gene and cell therapy and has been a key factor in the recent resurgence of this field, but there is still significant fundamental and translational work to realize the full promise of these technologies for widely treating human disease.” References: 1. Xu, L., Park, K.H., Zhao, L.X., Xu, J., El Refaey, M., Gao, Y.D., Zhu, H., Ma, J.J. & Han, R.Z. (2016) CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice. Molecular Therapy. 24(3):564-569. 2. Vanden Driessche, T. & Marinee K., Chuah, M.K. (2016) CRISPR/Cas9 Flexes Its Muscles: In Vivo Somatic Gene Editing for Muscular Dystrophy. Molecular Therapy. 24(3):414-416. 3. Aartsma-Rus, A., Ginjaar, I.B. & Bushby, K. (2016) The importance of genetic diagnosis for Duchenne muscular dystrophy. Journal of Medical Genetics. 53(3):145-151. 4. Maeder, M.L. & Gersbach, C.A. (2016) Genome-editing Technologies for Gene and Cell Therapy. Molecular Therapy. 24(3):430-446. Karl A. Bettelheim 20.3.2016